The United States of America v. Gilead Sciences, Inc. et al
Case Number:
1:19-cv-02103
Court:
Nature of Suit:
Judge:
Firms
Companies
Sectors & Industries:
-
May 09, 2024
Judge Clarifies Gilead Didn't Directly Infringe HIV Drug IP
A Delaware federal judge on Thursday rejected Gilead Sciences' request to amend her judgment finding that two medications in its HIV prevention regimen, Truvada and Descovy, directly infringed the government's invalidated patents, but clarified her judgment to say that non-party patients or physicians committed the infringement.
-
May 02, 2024
Feds Call Out Gilead's Efforts To Revise HIV Drug IP Judgment
The U.S. Department of Justice has asked a Delaware federal judge to reject Gilead Sciences' motion to modify a judgment finding that two medications in its HIV prevention regimen directly infringe voided patents owned by the government, arguing that the pharmaceutical company's attempt to rewrite the judgment is "unnecessary as well as improper."
-
March 22, 2024
Gilead's Win Upheld In Billion-Dollar HIV Drug Patent Case
A Delaware federal judge on Friday largely upheld a jury's verdict rejecting the government's potentially billion-dollar claim that Gilead Sciences Inc. infringed patents covering HIV drugs, ruling that the jury was correct in finding Gilead didn't cause doctors and patients to infringe.
-
June 21, 2023
Feds Fight Gilead's Win In Billion-Dollar HIV Patent Trial
The U.S. government urged a Delaware federal judge Tuesday to overturn a jury's verdict invalidating three federal patents on HIV treatments and clearing drugmaker Gilead Sciences Inc. of claims it infringed the patents while racking up billions in sales.
-
June 01, 2023
Gov't Told To Keep Fighting 'Unexpected' HIV Patent Loss
The International Planned Parenthood Federation and more than 30 other organizations have thrown their support behind the U.S. government after a Delaware federal jury invalidated three federal patents on HIV treatments and cleared drugmaker Gilead of infringement claims, arguing that the government must "continue to press its case" through an appeal or other means.
-
May 09, 2023
Jury Rejects Feds' Claims Gilead Infringed HIV Drug Patents
A six-member federal jury in Delaware rejected a potential billion-dollar government claim Tuesday that Gilead Sciences Inc. infringed government-owned patents when it fielded its Truvada and Descovy drugs to treat or reduce the risk of HIV infections.
-
April 27, 2023
IP Forecast: Gov't To Face Off Against Gilead In Delaware
In one of its first-ever patent infringement cases against a private company, the federal government next week will argue before a Delaware jury that Gilead is making billions of dollars in sales from HIV treatments that allegedly violate government-owned patents. Here's a look at that case — plus all the other major intellectual property matters on deck in the coming week.
-
April 04, 2023
Gilead, DOJ Allowed To Redact Remaining Docs In Patent Row
The federal government and Gilead Sciences Inc. got approval from a federal judge Tuesday to redact a limited number of documents after making public dozens of previously sealed filings in response to a third-party challenge, ahead of a May trial on their patent dispute over HIV drugs Truvada and Descovy.
-
January 24, 2023
Gilead Wants US To Face Defenses Before HIV Patent Trial
Gilead wants a Delaware federal judge to split up parts of the U.S. government's patent suit over brand-name HIV treatments Truvada and Descovy, saying the court should hear certain counterarguments before moving on with the rest of the case.
-
December 06, 2022
Gov't Says Gilead Can't Shake HIV Drug Patent Suit
The U.S. government has urged a Delaware federal judge not to let drugmaker Gilead Sciences Inc. escape its patent suit over brand-name HIV treatments Truvada and Descovy, arguing that clear authority gives it standing to assert its government-owned patents.